1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

ASH 2014: Acceleron drugs improve anemia in blood disorders

 
• By Mandy Jackson

Acceleron Pharma's lead product candidates luspatercept and sotatercept reduced or eliminated transfusion dependence for many patients with beta-thalassemia and myelodysplastic syndromes (MDS), but the company's partner Celgene is likely to take only one of the two drugs into later-stage development.

Acceleron Pharma's lead product candidates luspatercept and sotatercept reduced or eliminated transfusion dependence for many patients with beta-thalassemia and myelodysplastic syndromes (MDS), but the company's partner Celgene is likely to take only one of the two drugs into later-stage development.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 
• By Alaric DeArment

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

 
• By Alaric DeArment

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.